William F. Hahne
Corporate Officer/Principal bij BIO-PATH HOLDINGS, INC.
Profiel
William F.
Hahne is currently the Vice President-Clinical Research at Bio-Path Holdings, Inc. He previously worked as the Executive Director-Clinical Research at Eisai, Inc. from 1997 to 2002, Vice President-Clinical Development at CuraGen Corp.
from 2003 to 2005, VP-Clinical Development & Medical Affairs at Imunon, Inc. in 2006-2007, and Vice President-Medical at Vion Pharmaceuticals, Inc. He has an undergraduate degree from Grinnell College and a doctorate from Cornell University.
Actieve functies van William F. Hahne
| Bedrijven | Functie | Begin |
|---|---|---|
| BIO-PATH HOLDINGS, INC. | Corporate Officer/Principal | - |
Eerdere bekende functies van William F. Hahne
| Bedrijven | Functie | Einde |
|---|---|---|
| IMUNON, INC. | Chief Tech/Sci/R&D Officer | 01-12-2007 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Chief Tech/Sci/R&D Officer | 01-01-2005 |
Eisai, Inc.
 Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Chief Tech/Sci/R&D Officer | 01-01-2002 |
Vion Pharmaceuticals, Inc.
 Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Chief Tech/Sci/R&D Officer | - |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Chief Tech/Sci/R&D Officer | - |
Opleiding van William F. Hahne
| Grinnell College | Undergraduate Degree |
| Cornell University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| IMUNON, INC. | Health Technology |
| BIO-PATH HOLDINGS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Health Technology |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Health Technology |
